INTRODUCTION
Liver disease is increasing in incidence globally. Viral hepatitis (particularly hepatitis B and C) represents a massive healthcare burden which is set to increase in the coming decades. An indicator of this trend is the recent groundbreaking recommendation by the U.S. Advisory Committee on Immunization Practices (AICP) that all U.S. children be vaccinated against hepatitis B infection at birth [1] . Cirrhosis is the eighth leading cause of death by disease in the U.S.A. In the U.K., the cirrhosis death rate rose in women from 5 per 100 000 deaths in 1994 to 6.7 in 1999, and in men from 7.3 to 10.9 per 100 000 over the same period. Cirrhosis of the liver now kills more women than cervical cancer [2] . In the face of this, the therapeutic repertoire for the treatment of liver disease remains limited. Orthotopic liver transplantation is the only effective treatment for severe liver failure, but has several disadvantages, including limited donor liver availability and the commitment of recipients to lifelong toxic immunosuppression; in addition, patients can be excluded from transplantation due to psychiatric or medical contraindications. Hepatology has not so far benefited from the synthesis of an effective artificial organ, unlike mechanical ventilation in respiratory medicine or dialysis in renal failure. Indeed, recent studies to develop an artificial liver have illuminated the fact that it is likely that all cellular components and threedimensional structures (not only hepatocytes) of the liver will have to be reconstituted in order to subserve differentiated hepatic functions ex vivo. Effective alternative treatments to liver transplantation are urgently required.
Common to many aetiologies of liver disease is an inflammatory response. The key components of this response are an expanding family of related chemotactic cytokines now known as chemokines. Chemokines are small-protein inflammatory mediators that were classically known for their elicitation of inflammatory cells from the vasculature. However, contemporary studies show that these ubiquitous factors impinge on many facets of biology, including haematopoiesis, angiogenesis and mitogenesis. Owing to their involvement in a number of pathological processes, chemokines and their receptors represent important therapeutic targets. Prevention of inflammatory cell recruitment by blockade of the relevant chemokine receptor\ligand pair presents a novel mode of therapy that can act upstream of the nonspecific anti-inflammatory therapies currently in use. In addition, chemokine receptors are G-protein-coupled seven-transmembrane receptors, which have proven to be excellent pharmaceutical targets for many diseases [3] . Novel therapies including small-molecule chemokine inhibitors, and virally encoded, recombinant and genetically engineered chemokines, are emerging rapidly. For example, the number of small-molecule inhibitors of chemokine receptors is growing in the patent literature, and reports both in the literature as well as at conferences in the field have shown these inhibitors to be effective in inflammatory disease models, as well as inhibiting HIV-1 infection and spread [3] .
At present, chemokines are separated into four distinct structurally and functionally related families according to the relative positioning of the two cysteine residues at their N-terminus [4, 5] . The CC chemokine family have two juxapositioned cysteine residues, and include the monocyte chemoattractant proteins (MCP1-MCP5), eotaxin, RANTES (regulated on T cell activation, normal T cell expressed and secreted) and macrophage inflammatory proteins (MIPs). In general, the CC family is chemotactic for mononuclear cells. The CXC chemokine family is characterized by the presence of a nonconserved single amino acid (X ) between the two Nterminal cysteines. The CXC family is further subdivided into ELR-positive and ELR-negative CXC chemokines. The ELR chemokines have a three-amino-acid motif, comprising glutamine (E), leucine (L) and arginine (R), immediately adjacent to the CXC motif. The ELR CXC chemokines include interleukin 8 (IL8), cytokineinduced neutrophil chemoattractant (CINC), MIP2, epithelial neutrophil-activating protein 78 (ENA78), growth-related oncogene α (GROα), GROβ, GROγ and CXCR1  CXCL8, CXCL6  CXCR2  CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8  CXCR3  CXCL9, CXCL10, CXCL11, CXCL13  CXCR4  CXCL12  CXCR5  CXCL13  CXCR6  CXCL15 CCR1 CCL3, CCL5, CCL7, CCL8, CCL14, CCL15, CCL16, CCL23 CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 CCR3 CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL24, CCL26 CCR4 CCL17, CCL22 CCR5 CCL3, CCL4, CCL5 , CCL16  CCR6  CCL20  CCR7  CCL19, CCL21  CCR8  CCL1, CCL16  CCR9  CCL25  CCR10  CCL7, CCL25, CCL27, CCL28  CCR11  CCL8, CCL13   CX3CR1  CX3CL1  XCR1  XCR1 KC (a murine homologue of GRO). The non-ELR CXC chemokine family includes interferon-γ (IFNγ)-inducible protein 10 (IP10) and monokine induced by IFNγ (MIG). The ELR motif is important in chemokine ligand binding. The ELR-positive chemokines can bind to CXC chemokine receptor 1 (CXCR1) and\or CXCR2, while the non-ELR chemokines bind CXCR3. Table 1 lists human chemokine receptors and their associated ligands. The ELR-positive CXC chemokines are important neutrophil chemoattractants and induce angiogenesis. In contrast, non-ELR CXC chemokines are chemotactic for mononuclear cells and inhibit angiogenesis. The C and CXC3C families of chemokines each contain only a single member, lymphotactin and fractalkine (or neurotactin) respectively. Lymphotactin is a T cell chemotactic factor. Fractalkine is a unique chemokine in both its receptor and its structure, which contains a transmembrane glycoprotein and a chemokine domain at the end of an extended mucin-like stalk. Fractalkine occurs in both membrane-bound and soluble forms, and represents a novel regulator of leucocyte chemotaxis and adhesion. Originally, chemokines were isolated from stimulated or unstimulated cultured cells and characterized on the basis of their biological functions, mainly in relation to their chemoattractant activity. More recently, screening of cDNA libraries has been replaced by searching expressed sequence tag (EST ) databases for chemokine-like sequences. These strategies to identify new chemokines, along with the intense interest of the pharmaceutical industry in the light of the potential anti-HIV properties of chemokines, has led to an explosion in the numbers of chemokines identified in both the CXC and CC families. This led to a consensus conference to produce a more rational nomenclature for all chemokines, and this nomenclature is used throughout the present review [6] . The increase in the numbers of chemokines has also outstripped our understanding of their role in pathological processes, particularly with regard to the pathogenesis of liver disease. This review describes each chemokine characterized (at the time of writing) and discusses its known or potential role in the physiology and\or pathophysiology of the liver.
CXC CHEMOKINES CXCL1 (GROα), CXCL2 (GROβ) and CXCL3 (GROγ)
This sub-family of human chemokines was one of the first to be characterized, along with the murine homologue of GRO (known as KC) and the rat homologue (CINC). The GRO proteins are the products of three separate genes. Both rodent and human chemokines bind to a single receptor, CXCR2. CXCR2 and CXCL1, CXCL2 and CXCL3 are widely distributed and are expressed within the liver. Cellular expression occurs in stimulated hepatocytes, macrophages (Kupffer cells), activated stellate cells and endothelial cells [7] [8] [9] [10] . Increased hepatic expression of GRO, KC or CINC has been reported in a number of liver disorders. Hepatic ischaemia\reperfusion (I\R), which may occur during liver surgery or resuscitation following hypotension, induces the hepatic expression of tumour necrosis factor α (TNFα) and KC or CINC in the mouse and rat respectively [11, 12] . Immunoneutralization of KC or inhibition of Kupffer cell function with gadolinium chloride reduces both hepatic neutrophil infiltration and liver injury. In mice, increased hepatic expression of KC also occurs during sepsis, lipopolysaccharide injection, hepatic infection and paracetamol poisoning [13] [14] [15] . Increases in hepatic CINC levels have also been reported with similar experimental manipulations in rats [16, 17] . In humans, hepatic expression of GRO occurs in disorders particularly associated with neutrophil infiltration, such as alcoholic hepatitis [18] , although increases also occur in other disorders [19] .
However, the relationship between increased hepatic GRO\KC\CINC expression, hepatic polymorphonuclear neutrophil leucocyte infiltration and hepatic injury is complex. Administration of 10"! plaqueforming units (p.f.u.) of recombinant adenovirus containing CINC cDNA to rats increased hepatic and circulating CINC concentrations and neutrophil counts, and induced severe hepatic injury with inflammation, compared with a control group administered an adenovirus containing luciferase [20] . However, the control adenovirus also caused a significant increase in hepatic neutrophilia compared with saline-treated controls. This increase in neutrophils was associated with histological and biochemical hepatic injury in the control adenovirustreated group, but hepatic CINC levels were similar to those in saline-treated controls. Immunoneutralization of KC in a sepsis model did not reduce hepatic neutrophil infiltration, but decreased liver injury [13] . Alternatively, murine hepatic I\R is associated with increased KC expression, and chemokine inhibition is associated with reduced neutrophil influx and hepatocellular injury [21] . Neutralization of CINC in a rat sepsis model also decreased neutrophil influx into the liver and reduced injury [22] . These conflicting data with regard to the significance of increased levels of GRO\KC\CINC may relate to the redundancy of the chemokine system. Increases in other CXC chemokines, such as CXCL8 (IL8\MIP2) and CXCL6 (ENA78), commonly accompany increases in hepatic GRO\KC\CINC levels. Others have shown that intravenous injection of KC led to minor activation of peripheral blood neutrophils and sinusoidal neutrophil sequestration compared with intravenous MIP2 [23] . The latter chemokine is also a more potent neutrophil chemoattractant than KC. Alternatively, the mode of hepatic injury may dictate the response to neutralization of GRO\KC\CINC. A recent paper reported increased hepatic expression of KC (and MIP2) in vivo following Fas-mediated apoptosis, which was accompanied by hepatic neutrophil infiltration, thus linking apoptosis with an inflammatory response [24] . Although inhibition of KC lowered hepatic neutrophil influx, liver injury, as assessed by histology and circulating transaminases, was similar to that in controls. These data suggest that liver injury induced by Fasmediated apoptosis may result in hepatic inflammation, but the severe forms of liver injury reported in this model proceed independently of increased hepatic GRO\KC\CINC levels and neutrophil numbers. Lastly, the levels of KC\CINC induced by a stimulus, both in the liver and systemically, and the subsequent degree of neutrophil accumulation and activation may affect the response to immunoneutralization (see CXCL8 below).
CXCL5 (ENA78)
CXCL5 (ENA78) was first isolated from the conditioned media of IL1β-or TNFα-treated epithelial cells. CXCL5 has a high degree of identity with other CXC chemokines, and its mRNA has been located within the liver. Following appropriate stimuli, human hepatocytes, endothelial cells and macrophages (Kupffer cells) can express CXCL5 [7] . This chemokine acts by binding to CXCR2, which is also expressed on hepatocytes. Hepatic CXCL5 expression is increased in experimental alcoholic liver disease and is correlated with the degree of necroinflammatory change. TNFα induces hepatic CXCL5 expression in both the ischaemic and non-ischaemic liver lobes following I\R in rats [25] . IFNγ abrogates this increase in CXCL5 concentration [26] . This effect of IFNγ on the hepatic CXCL5 concentration was not associated with any significant reduction in neutrophil infiltration in either liver lobe following I\R, but did reduce the severity of liver injury, as assessed by serum aminotransferases. However, immunoneutralization of CXCL5 reduces both hepatic neutrophil influx and liver injury. Other studies have revealed that systemic release of TNFα from the liver following hepatic I\R results in neutrophil-mediated lung injury that is dependent on TNFα-induced CXCL5 expression [27] . CXCL5 may also have a permissive effect on hepatic regeneration. CXCL5 expression is increased in rodent liver following partial hepatectomy. Immunoneutralization of CXCL5 decreased the rate of hepatic regeneration, but did not affect the recruitment of neutrophils seen in this model. Furthermore, CXCL5 induces the proliferation of primary rodent hepatocytes in vitro [28] .
CXCL8 (IL8) and MIP2
CXCL8 (IL8) was one of the first chemokines to be identified and characterized. Reflecting its biological activity, IL8 had several different names before being rechristened CXCL8. Many different cells produce this chemokine following appropriate stimuli. Exposure of hepatocytes to stimuli such as oxidative stress, ethanol, IL1β and TNFα results in the production of CXCL8 [7] . This chemokine can also be produced by endothelial cells, Kupffer cells, biliary epithelial cells and stellate cells [29] [30] [31] . The biological effects of CXCL8 are mediated by its binding to CXCR1 and CXCR2. No mouse homologue has been described, but human CXCL8 most closely resembles murine MIP2 and rat CINC. For the purposes of this review the biological effects of MIP2 will be discussed along with those of IL8 (CXCL8).
Many studies have measured circulating chemokine concentrations in patients with liver disease. CXCL8 is perhaps the best studied. The highest concentrations are reported in patients with alcoholic hepatitis, with lower concentrations associated with other histological forms of alcoholic liver disease [32, 33] . Circulating CXCL8 is also increased in patients with viral hepatitis or acute graft-versus-host disease (GVHD), and following liver transplantation [34] [35] [36] . In general, increased levels of CXCL8 correlate with reduced survival and impaired hepatic function, and arise from increased production and\or reduced hepatic clearance. We have found levels of CXCL8 to be significantly higher in hepatic venous than in portal venous blood, implying increased hepatic production in patients with chronic alcoholic liver disease.
The pathophysiological significance of these increased circulating CXCL8 concentrations is not clear. In murine studies, increased hepatic neutrophil accumulation occurs in CXCL8 transgenic mice and following systemic administration of high doses of MIP2 [23, 37] . However, the latter study did not find any infiltration of neutrophils into the hepatic parenchyma, and concluded that increased circulating chemokine concentrations may direct neutrophils towards, but not into, liver tissue. Previous studies using non-specific chemoattractants have shown reduced neutrophil chemotaxis in patients with liver cirrhosis, especially alcoholic cirrhosis [58, 59] . This defect was partly due to a circulating inhibitor of neutrophil chemotaxis [38, 39] . Using a modified Boyden chamber technique, we found reduced neutrophil chemotaxis in response to CXCL8 (and CXCL1) in patients with liver disorders, including alcoholic cirrhosis and acute liver failure [40] . This defective chemotaxis may partly explain the high risk of infection in these patients. The defective IL8-induced chemotaxis is worse following simulated gastrointestinal haemorrhage and improves after liver transplantation [41] . Despite the increased circulating CXC chemokine concentrations associated with these conditions, expression of CXCR1 and CXCR2 in neutrophils was normal [42] . These data suggest that the defect in neutrophil chemotaxis in response to CXC chemokines in patients with liver failure is due to abnormal chemokine-chemokine-receptor interactions and\or post-receptor signalling abnormalities.
CXCL8 (like other chemokines) is expressed in the hepatic parenchyma at sites of inflammation during alcoholic hepatitis, and correlates with the neutrophilic infiltration characteristic of this form of liver injury. In alcoholic cirrhosis the expression of CXCL8 was more restricted to inflammatory cells and endothelium in fibrous septa and portal tracts [43] . Experimental models of alcoholic liver disease also reveal increased plasma and hepatic MIP2 concentrations, which also correlate with the extent of necro-inflammatory changes in the liver [44] . Isolated Kupffer cells from alcohol-fed rats spontaneously produced 4-fold more MIP2 than those from pair-fed controls, suggesting that Kupffer cells are a major source of MIP2 in this model [45] . In addition to the potential for recruiting neutrophils, MIP2 was also directly toxic to hepatocytes prepared from chronic alcohol-fed animals. This effect could be blocked cycloheximide, implicating protein synthesis in the hepatotoxic effects of MIP2 [45] . In a sepsis model induced by caecal ligation and puncture, the expression of CXC chemokines, including MIP2, is dramatically upregulated in the liver [14] . Increased hepatic MIP2 concentrations also arise from enhanced Kupffer cell production, as shown by the decrease following gadolinium chloride administration. Immunoneutralization of MIP2 decreased neutrophil influx into the liver, reduced hepatic injury and improved survival following caecal ligation and puncture [14] .
Systemic adenoviral gene therapy is associated with severe acute hepatocellular injury. Chemokines, including MIP2, play important roles in both mediating and mitigating this injury, related in part to their relative abundance in the liver and their intended cellular targets. For example, in mice given a dose of 10"! p.f.u. of a control recombinant adenovirus containing β-galactosidase or green fluorescent protein, significant increases in hepatic MIP2 concentrations and neutrophil numbers in the liver were noted [20] . This control adenovirus also caused a 4-fold increase in hepatic neutrophil influx and increased serum transaminases compared with saline-injected controls, indicating that the adenovirus vector alone causes liver injury, presumably via stimulating neutrophil influx. Other studies have suggested that overexpression of ELR CXC chemokines in gene targeting may be beneficial [46] . In mice receiving the lower dose of 10) p.f.u. of adenovirus containing rat MIP2 cDNA, hepatic injury was markedly lower than in mice that received an empty cassette. The lack of liver injury was further illustrated when the adeno-MIP2-treated group was challenged with paracetamol. The adeno-MIP2 treatment protected the mice from paracetamol-induced injury and, surprisingly, caused a decrease in neutrophil infiltration and an increase in hepatocyte proliferation. In the latter model of hepatic failure, paracetamol administration alone increased liver concentrations of MIP2, and inhibiting hepatic MIP2 expression increased liver injury and mortality [47] . These data suggest two contrasting effects of CXC chemokines in modulating hepatic injury and repair, related to the relative concentrations of the chemokines and the target cells within the liver. Very high concentrations of CXC chemokines increase peripheral leucocyte recruitment to the liver. In contrast, lower concentrations of CXC chemokines are hepatoprotective and fail to induce hepatic neutrophilia. Cadmium poisoning also induces acute severe hepatocellular injury. In contrast with our findings with paracetamol poisoning, mortality in CXCL8 transgenic mice was increased following acute cadmium exposure. Surprisingly, the increased mortality was associated with reduced hepatic neutrophil infiltration [48] .
These novel hepatoprotective effects of CXC chemokines, such as CXCL8, may be related in part to their ability to stimulate hepatocyte proliferation [28] . CXCL8 functions as an autocrine growth factor for human hepatoma cell lines. CXCL8 and other CXC chemokines, including CXCL5 and MIP2, also stimulate primary rodent hepatocyte proliferation in vitro. Like other biological responses, these mitogenic effects of CXCL8 (and other CXC chemokines such as CXCL5) are inhibited by the ELR-negative chemokines CXCL9 and CXCL10 [28] . Using a rat partial hepatectomy model to study hepatocyte proliferation in vivo, MIP2 and CXCL5 concentrations were up-regulated, and immunoneutralization of these chemokines delayed hepatic regeneration, an effect that occurred without influencing hepatic neutrophil recruitment [28] .
MIP2 has also been implicated in the response of the liver to I\R. TNFα up-regulates the hepatic expression of vascular endothelial cell adhesion molecules and of CXC chemokines such as MIP2 in this model [21] . Immunoneutralization of MIP2 led to a decrease in hepatic neutrophil influx and injury. Furthermore, treatment with anti-inflammatory cytokines, such as IL10 or IL13, resulted in decreased TNFα and MIP2 levels, which were associated with decreases in neutrophil accumulation and hepatic injury [49, 50] . The mode of action of IL10 and IL13 appears to depend on a decrease in nuclear factor κB and increased STAT6 (signal transducer and activator of transcription 6) activation respectively. Thus manipulation of chemokine levels may provide important prophylactic treatment in liver surgery that may lead to I\R injury.
Injection of concanavalin A induces non-specific T cell activation, with production of TNFα and IFNγ and immune-mediated liver injury. A recent study found increased plasma MIP2 levels (but did not measure hepatic concentrations) following concanavalin A injection, associated with neutrophil influx into the liver; immunoneutralization of MIP2 was partially protective, with an approx. 50 % reduction in plasma transaminases [51] . This protective effect was also associated with a partial decrease in hepatic neutrophil influx. Presumably other CXC chemokines and CC chemokines are induced in this model, and are important in mediating both neutrophil and lymphocyte influx into the liver.
CXCL9 (MIG)
CXCL9 is produced by monocytes\macrophages, neutrophils and other inflammatory cells, and by stromal cells such as hepatocytes, following either stimulation by IFNγ or viral infection [52, 53] . In vivo treatment with IFNγ or IL12\IL2 up-regulates both hepatocyte and non-parenchymal cell expression of CXCL9 [7] . CXCL9 acts by binding to CXCR3. Unlike other CXC chemokines, CXCL9, CXCL10 and CXCL11 are not chemotactic for neutrophils, but induce chemotaxis of activated lymphocytes [52] . These chemokines can also inhibit the biological functions of CC chemokines by binding to CC chemokine receptor 3 (CCR3) [54] . CXCL9 expression occurs on sinusoidal epithelial cells in both normal and hepatitis C-infected liver tissue, and expression is up-regulated in the latter tissue [55] . This expression of CXCL9 is associated with hepatic infiltration by CXCR3-positive T cells, suggesting that the interaction between CXCR3 and its ligands is important in recruiting lymphocytes to sites of inflammation within liver tissue. Whether this particular chemokine-chemokine-receptor interaction is harmful or beneficial to the liver remains to be defined. In contrast with the situation in hepatitis C infection, in which CXCL10 appears to be more important, CXCL9 is strongly expressed on vascular and sinusoidal endothelium in primary hepatic tumours, and induces the chemotaxis of tumour-infiltrating lymphocytes [56] . CXCL10 is not expressed on endothelium in either primary or secondary hepatic tumours. Thus, in the case of cancer, the augmentation of CXCL9 expression to perpetuate the pro-inflammatory response may provide a beneficial therapeutic option that remains to be investigated. Expression of CXCL9 and of other CXCR3 ligands (i.e. CXCL10 and CXCL11) is induced in rejecting hepatic allografts [57] . This was correlated with the increased expression of CXCR3 on circulating and hepatic lymphocytes, suggesting that these chemokines may be therapeutic targets for the treatment of allograft rejection.
CXCL10 (IP10)
CXCL10 (IP10), in common with CXCL9 (MIG), is released from cells, including hepatocytes, stimulated by IFNγ. CXCL10 also binds to CXCR3. CXCL10 is expressed in the liver during experimental models of sepsis and hepatic I\R. In the latter model, pretreatment with IFNγ to up-regulate IP10 shifts hepatic expression from ELR-positive chemokines to non-ELR-positive CXC chemokines, such as CXCL10 [26] . This alteration in the chemokine balance resulted in a decrease in liver and lung injury, but had no effect on hepatic neutrophil influx [26] . Thus manipulation of chemokine levels may provide important prophylactic treatment in liver surgery that may potentially lead to I\R injury.
Hepatic CXCL10 expression is also increased in experimental models of alcoholic liver disease. Highest expression was reported in the animals with the greatest degree of liver injury [44] . CXCL10, in common with CXCL9, is expressed in liver tissue from patients with hepatitis C infection, and relates to hepatic infiltration with CXCR3-positive T cells within the hepatic lobules [55] . Expression of CXCL10 is more specific for hepatic inflammation than that of CXCL9, and is undetectable in normal liver tissue. In vitro, sinusoidal lining endothelial cells release higher concentrations of CXCL10 than of CXCL9. As with CXCL9, whether this interaction aggravates or attenuates hepatic injury is not clear. Hepatic expression of CXCL10 is also induced in a murine model of hepatitis B infection [58] . Interestingly, inhibition of CXCL10 reduced hepatic inflammation and liver injury, but did not affect the anti-viral potential of transferred virus-specific cytotoxic lymphocytes, which is dependent on IFNγ production.
In contrast with the potential for CXCL10 to augment immune-mediated liver injury through the recruitment of CXCR3-positive lymphocytes, recent studies have demonstrated a hepatoprotective effect of CXCL10 [59, 60] . Paracetamol poisoning induces hepatic CXCL10 and CXCR3 expression [60] . Recombinant CXCL10 administered 10 h after paracetamol poisoning, when liver injury is established, improves murine survival and hepatic histology. This effect is mediated via induction of CXCR2 expression on hepatocytes, and is limited by the immunoneutralization of CXCR2 [60] . Others have suggested that the hepatoprotective effects of CXCL10 are mediated by the stimulation of hepatocyte growth factor production from hepatocytes [59] . Alternatively, human hepatic stellate cells are important in hepatic regeneration following acute injury, and also express CXCR3 [61] . Exposure of these stellate cells to CXCL10 activates a number of intracellular signalling pathways and induces their chemotaxis, but not proliferation, providing another potential effect of CXCL10 in the liver's response to injury.
CXCL11 [IFNγ-inducible T cell α-chemoattractant (I-TAC)]
CXCL11 is a chemokine that was recently isolated from IFNγ-stimulated human astrocytes. The release of this chemokine can also be stimulated by IL1β in the same cells, and in other cell types such as monocytes\ macrophages treated with pro-inflammatory cytokines, microvascular endothelial cells, keratinocytes and dermal fibroblasts. Murine CXCL11 has also been identified, and is induced in macrophages by IFNγ and lipopolysaccharide in vitro and by endotoxaemia in vivo in the lung, heart, small intestine and kidney [62] . The induction of CXCL11 is strongly attenuated by glucocorticoids, and in some cell types by the Th2 cytokines IL10 and\or IL4. Interestingly, human neutrophils treated with TNFα and IFNγ release CXCL11, suggesting that this chemokine can link the innate and adaptive immune responses by inducing T cell chemotaxis [63] . CXCL11 binds to CXCR3, and is of higher potency and efficacy when compared with the biological responses induced by CXCL9 or CXCL10 in activated T cells and cells transfected with CXCR3. The expression of human CXCL11 has been identified in pancreas, lung, thymus and spleen, but little expression was identified within the liver. CXCL11 and other CXCR3 ligands have been implicated in heart allograft rejection [64] , but the role of this chemokine in the pathogenesis of liver disease remains to be explored. The characteristics of the binding of CXCL11, CXCL10 and CXCL9 to CXCR3 differ, and so the biological effects of CXCL9 and CXCL10 in liver disorders cannot be automatically assumed to also occur with CXCL11.
CXCL12 [stromal-derived factor 1 (SDF1)]
CXCL12 is constitutively expressed and widely distributed in normal human and murine tissues, including the liver. Human and mouse CXCL12 are very similar, differing by only a single amino acid. CXCL12 is a highly effective lymphocyte (both T and B cell) chemoattractant, but is also chemotactic for monocytes, neutrophils and haemopoietic CD34j stem cells [65] [66] [67] . CXCL12 is also able to inhibit entry of HIV into cells expressing CXCR4 [68] . The specificity of the interaction between CXCL12 and CXCR4 is illustrated by the abnormalities found in CXCL12 or CXCR4 knockout mice [69, 70] . These two types of genetically modified mice have similar defects, which include cerebellar, vascular and cardiac abnormalities, and defective foetal liver B cell lymphopoiesis. Studies in aborted human foetuses have demonstrated CXCL12 expression in biliary ductal plate epithelial cells, which may support B cell production in the late stages of gestation. However, the role of CXCL12 in the development of the biliary ductal plate is not clear, as CXCL12 or receptor knockout animals die either in utero or soon after birth [71] . A recent study showed that CXCL12 expression is induced in biliary epithelium in rejecting hepatic allografts, and this is correlated with infiltration by CXCR4-expressing lymphocytes [57] . The role of this chemokine in the pathogenesis of other biliary disorders remains to be defined. Although transformed hepatoma cell lines express CXCR4, the receptor is uncoupled from downstream signalling events [72] , suggesting that the binding of CXCL12 to its receptor is not a candidate chemokine-chemokine-receptor interaction important in determining the metastasis of hepatoma cells (unlike in breast carcinoma [73] ). In addition, immunohistochemical studies have shown reduced CXCL12 expression in hepatocellular carcinoma compared with other chronic liver diseases, such as hepatitis C infection [74, 75] .
Other CXC chemokines
CXCL4 is released from the α granules of platelets and, like other CXC chemokines, is chemotactic for neutrophils; however, CXCL4 is also chemotactic for other cell types, including monocytes and fibroblasts. The receptor via which this chemokine exerts its biological effects has yet to be characterized. Uptake and intracellular processing of CXCL4 by hepatocytes has been reported via the endosome pathway [76] . Increased circulating CXCL4 levels have been reported in patients with decompensated cirrhosis, reflecting the platelet activation associated with this disease or reduced clearance by the damaged liver [77] . Increased circulating CXCL4 has also been reported after liver transplantation [78] . However the roles of CXCL4 and other CXC chemokines, such as CXCL6 (granulocyte chemoattractant protein 2, GCP2), CXCL7 (neutrophil-activating protein 2, NAP2), CXCL13 (B-cell-attracting chemokine-1, BCA-1; Blymphocyte chemoattractant, BLC), CXCL14 (breast and kidney expressed chemokine, BRAK; bolekine), CXCL15 (Lungkine) and CXCL16 (SexCKine), in the pathogenesis of liver diseases remain to be characterized. As discussed above, although further studies may show some of these chemokines to be expressed in inflammed liver tissue, their role in the pathogenesis of liver diseases may be more complex than the recruitment of immune cells.
CC CHEMOKINES
To date, 28 CC chemokines have been identified and characterized. However, for many of these chemokines, especially the more recently characterized, their role in the pathogenesis of liver diseases remains to be elucidated. The following discussion focuses on those CC chemokines for which data exist with regard to a role in liver disorders.
CCL2 [MCP1, monocyte chemotactic and activating factor (MCAF)]
CCL2 was first purified from lipopolysaccharide-or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, a glioblastoma cell line and THP1 cells. The expression of CCL2, and its murine homologue JE, can be induced in many cell types, including hepatocytes, Kupffer cells and stellate cells [79] . Interestingly, transfection of a transformed hepatocyte cell line with the hepatitis B X protein down-regulated CCL2 expression [80] . The effects of CCL2 are mediated by binding to CCR2, which is expressed on monocytes, T lymphocytes and basophils [79] .
In a model of sepsis induced by caecal ligation and puncture, the expression of CC chemokines, including CCL2, is dramatically up-regulated in the liver. The cellular source of this increased CCL2 expression is not known. However, other studies have shown that CCL2 levels are elevated in serum and liver due to its production from monocytes\macrophages [81, 82] . When these cells were inhibited with gadolinium chloride, there was a significant decrease in the systemic levels of CCL2 [83] . CCL2 is also released by Kupffer cells following I\R in response to both oxygen radicals and neutrophil elastase. When either of these stimuli is inhibited, hepatic CCL2 concentrations decrease and less liver injury is observed. In addition, CCL2 appears to be part of an amplification loop within the liver, since it is able to modulate polymorphonuclear leucocyte-dependent tissue injury via up-regulation of endothelial intracellular adhesion molecule-1 expression. These data implicate CCL2 in the recruitment of inflammatory cells to the liver, by acting at several sites in their movement from the circulation into the tissues.
In patients with alcoholic hepatitis, circulating concentrations of CCL2 were increased, and spontaneous production of CCL2 was increased in both intrahepatic and peripheral blood mononuclear cells [84] . This increased production was correlated with high serum transaminase levels, suggesting that CCL2 is linked with hepatocyte death in this disease. Furthermore, CCL2 and other chemokines such as CXCL8, CCL3 and CCL4 are all detected in the parenchyma at sites of inflammation in patients with alcoholic hepatitis. Experimental alcoholic liver disease also results in increased CCL2 expression. Hepatitis C infection is also associated with increased hepatic expression of CCL2; a concomitant increase in hepatic CCL2 and decrease in CXCL10 was correlated with a better response to IFN treatment in this disease [85] .
CCL2 may also play an important role in the perpetuation of hepatic injury and fibrosis. In cirrhosis, CCL2 expression is up-regulated in portal tracts, epithelial cells of regenerating bile ducts and active septa, activated stellate cells and Kupffer cells [86] . Infiltration of monocytes and macrophages into the portal tracts was correlated with increased CCL2 expression. In response to injury, hepatic stellate cells undergo a phenotypic change from lipid-storing, relatively quiescent cells into myofibroblast-like cells capable of increased matrix synthesis, contraction and cytokine\chemokine synthesis. Early studies showed CCL2 expression and release by activated stellate cells both in vivo and in vitro [87] . CCL2 is also chemotactic for hepatic stellate cells and stimulates various intracellular signalling pathways, including tyrosine kinases and phosphatidylinositol 3-kinases, but these cells do not express CCR2 [88] . These data suggest that there is another CCL2 receptor yet to be characterized. Stimulation of intracellular signalling pathways associated with proliferation and survival suggest that CCL2 may perpetuate the transformed and profibrotic myofibroblast phenotype and also recruit more stellate cells to the site of fibrosis. Thus therapies aimed at neutralizing this chemokine may decrease fibrogenesis.
More recent data from an experimental model of paracetamol poisoning have further elucidated the immunomodulatory effects of CCL2 [89, 90] . Hepatic concentrations of CCL2 increase significantly after paracetamol overdose in mice. However, in CCR2 knockout mice there was dramatically more liver injury compared with wild-type mice. This increase in paracetamol hepatotoxicity was related to an increase in the hepatic expression of the pro-inflammatory cytokines IFNγ and TNFα, suggesting that CCL2 can downregulate pro-inflammatory cytokine expression. Similar results have been observed in experimental sepsis. Paracetamol poisoning induces the production of reactive oxygen species in the liver. Free radicals can also stimulate CCL2 production in transformed stellate cells and Kupffer cells in vitro and in vivo in other oxidative liver injury models, e.g. carbon tetrachloride [87] . In contrast with paracetamol poisoning, antioxidant pretreatment with vitamin E dramatically reduced CCL2 concentrations following carbon tetrachloride. Thus CCL2 appears to play a conflicting role during oxidative injury in these two murine models, and further studies are needed to elucidate the underlying mechanism.
CCL3 (MIP1α)
CCL3 was initially characterized as one of two MIPs released from lipopolysaccharide-stimulated murine macrophages [91] . After sequencing these proteins, it was shown that they were identical with human LD78 and other gene products. Human and murine CCL3 bind to and activate cells via two chemokine receptors, namely CCR1 and CCR5. In addition to its effects on monocytes, CCL3 is a chemoattractant for T cells, B cells and eosinophils.
In experimental sepsis, the expression of CC chemokines, including CCL3, is dramatically upregulated in the liver. Increased hepatic CCL3 expression also occurs in chronic alcohol-fed rats, and in the inflammatory infiltrates of the liver, on sinusoidal lining cells and on intra-lobular bile ducts in the livers of mice with GVHD due to cell transfer [92, 93] . The CCL3 receptor CCR1 is expressed by liver-infiltrating CD8j T lymphocytes, peaking in the first week after cell transfer, but declining in the second week in this model. In contrast, CCR5 expression is low during the first week and increases dramatically during the second week after transfer. Neutralization of CCR5 or CCL3 decreased the infiltration of T lymphocytes into the liver and reduced liver damage, as assessed by serum transaminases. Similarly, in mice that received cells from CCL3 knockout mice, there was a decrease in the occurrence of GVHD. If these data could be reproduced in humans with GVHD, the interaction between CCL3 and CCR3 or CCR5 may be a novel therapeutic target.
Cytomegalovirus (CMV) infection is common following hepatic transplantation, and can lead to a severe acute intense hepatitis. Murine CMV (mCMV) infections are characterized by increased hepatic CCL3 expression [94] . Immunoneutralization of CCL3 during mCMV infection markedly decreased natural killer (NK) cell recruitment, while increasing the number of viral inclusion bodies in the liver. Similar findings were obtained in mCMV-infected CCL3 knockout mice. Thus the depletion of CCL3 decreased hepatic inflammation, but increased the mCMV viral load. Further studies are required to determine the clinical significance of these observations. CCL3 is also expressed at sites of inflammation during alcoholic hepatitis, and is released spontaneously by cultured peripheral blood mononuclear cells in this disease [84] . Observational studies have also implicated CCL3 (and CCL4) in the development of hepatic allograft rejection [95] . Expression of CCL3 is up-regulated in sinusoidal endothelium, central veins and infiltrating inflammatory cells in patients with rejection. Endothelial cell CCL3 expression is up-regulated early after the liver transplant operation, and CCL3 may thus be important in the initial recruitment of T cells into the graft, with subsequent amplification of the inflammatory response by the expression of CCL2 by the recruited cells. Successful treatment of allograft rejection with pulse steroid therapy is associated with down-regulation of endothelial CCL3 expression.
CCL4 (MIP1β)
In parallel with the identification of CCL3, CCL4 was also found to be secreted from lipopolysaccharidestimulated murine macrophages [91] . Cloning and sequencing of the gene for this chemokine showed that it was identical with several other human genes variously named ACT2, G26, HC21, H400, LAG1, AT744.1 and AT744.2. Unlike those of CCL3, the biological effects of CCL4 are mediated by binding to CCR5, but not to CCR1. Hence the biological effects of CCL4 are more restricted than those of CCL3.
Hepatic expression of CCL4 is increased in a number of experimental and clinical liver disorders. CCL4 is upregulated in experimental sepsis, and is also expressed in liver tissue from patients with alcoholic hepatitis, and may play a similar role in hepatic allograft rejection as described for CCL3 [84, 95] .
CCL5 (RANTES)
CCL5 was initially purified from thrombin-stimulated human platelets. However, CCL5 can be synthesized by many other cell types, including T cells, macrophages and liver-derived dendritic cells. CCL5 expression is induced in human hepatoma cells by bile acids, and may provide a link between cholestasis and inflammation in conditions such as primary biliary cirrhosis, sclerosing cholangitis and bile duct obstruction [96] . Kupffer cells can also produce CCL5, and expression is induced by ethanol [97] . CCL5 binds to several chemokine receptors (CCR1, CCR3 and CCR5) and therefore can interact with many different cell types, being chemotactic for monocytes, T cells, basophils and eosinophils.
Increased hepatic concentrations of CCL5 occur in viral hepatitis, localize to the site of hepatic inflammatory infiltrate and are correlated with the degree of liver injury, as determined by serum transaminases [98] . Adenoviral hepatitis is also associated with increased concentrations of CCL5, and increased hepatic expression of CCL5 has been reported in experimental alcoholic liver injury [99] . Hepatic eosinophil infiltration is pronounced in patients with hepatic allograft rejection or drug-induced hepatotoxicity [100] . In the latter condition, the hepatic expression of CCL5 is increased in some, but not all, patients [101] . Lipopolysaccharide injection also induces the expression of CCL5 in the liver; this is reduced following Kupffer cell depletion, suggesting that these cells are the source of CCL5 in vivo in this model.
CCL7 (MCP3)
CCL7 was first identified from cytokine-stimulated human oesteosarcoma cells, which can also secrete CCL2 (MCP1) and CCL8 (MCP2). Sequence analysis of the MCP3 gene showed a high degree of identity with the mouse MARC gene [102] . CCL7 is expressed in monocytes, pro-inflammatory-stimulated endothelial cells, smooth muscle cells and human CD34j cells. CCL7, like several other chemokines, binds to a number of different receptors, namely CCR1, CCR2, CCR3 and CCR10. Interestingly, CCL7 can bind to CCR5, but does not induce signal transduction or down-regulate receptor surface expression, and therefore will not inhibit HIV infection. CCL7 acts as a chemoattractant for monocytes, T lymphocytes, NK cells, dendritic cells, basophils and eosinophils. A CCL7 (and CCL8)-positive monocyte infiltration in portal tracts is a characteristic feature of primary biliary cirrhosis [103] . However, the biological significance of this finding with regard to the recruitment of inflammatory cells in this condition has not been defined.
CCL11 (eotaxin)
CCL11 was first isolated from bronchoalveolar lavage fluid from atopic guinea-pigs [104] . Human and murine CCL11 were subsequently isolated and characterized. CCL11 is a specific eosinophil chemoattractant, although it can also act on basophils through binding to the receptor CCR3. As discussed above, CCR3 can bind other chemokines, such as CCL7 and CCL5. CCL11 is expressed in foetal liver and, along with stem cell factor, is important in mast cell development [105] . Northern blot analysis has not shown constitutive expression in liver tissue from adult donors. However, CCL11 expression is found in the majority of patients with druginduced liver disease, a disorder that is associated with a heavy eosinophil infiltrate [101] .
CCL12 (MCP5)
CCL12 was identified from a murine genomic library and has yet to be isolated in humans [106] . It acts as a chemoattractant for monocytes, T lymphocytes and eosinophils by binding to CCR2. Constitutive expression of CCL12 was detected in lymph nodes, and its expression is markedly induced in activated macrophages. Up-regulation of CCL12 expression was also noted within the lungs following infection or allergen challenge. Immunoneutralization of CCL12 reduced bronchial reactivity in this model [107] . CCL12 has also been implicated in the pathogenesis of experimental allergic encephalomyelitis [108] . Lipopolysaccharide injection results in increased CCL12 concentrations in murine liver, and these increases are abrogated in Kupffer celldepleted mice, suggesting that tissue macrophages are the source of CCL12 in vivo [109] . However, the role of CCL12 in the pathogenesis of murine liver disorders remains to be defined.
CCL14 [human CC chemokine-1 (HCC-1)]
CCL14 was first isolated from the haemofiltrate of patients with chronic renal failure [110] . In common with CXCL12 (SDF1) it is expressed constitutively in a wide variety of normal tissues, including liver, and is found at high concentrations in normal plasma. A murine homologue has not been identified. Unprocessed CCL14 binds to CCR1, and is able to stimulate monocyte Ca# + flux and enzyme release, but not chemotaxis [111] . Proteolytic processing by serine proteases, such as plasmin and urokinase plasminogen activator, cleaves CCL14 to form a more active chemokine. This truncated form of CCL14 binds to other chemokine receptors, such as CCR3 and CCR5, and is chemotactic for a wide range of cell types, including T lymphocytes and eosinophils [112] . CCL14 is also able to stimulate the proliferation of bone marrow stem cells. Increased constitutive expression of this chemokine in the liver suggests that it has a role in the normal physiological trafficking of immune cells through the liver, but this requires clarification.
CCL15 (HCC-2, leukotactin-1)
CCL15 (HCC-2) was identified during the sequencing of the upstream region of the CCL14 gene [113] . In contrast with CCL14, CCL15 is expressed only in the gut and liver. It is similar to a number of other chemokines, including CCL23, CCL6, CCL18 and CCL 9\10, which contain six cysteine residues. CCL15 is chemotactic for monocytes and eosinophils, and acts by binding to the chemokine receptors CCR1 and CCR3. Further studies are required to determine the role of this chemokine in liver disorders.
CCL16 [HCC-4, liver-expressed chemokine (LEC), LMC, NCC-4]
CCL16 is expressed in IL10-activated monocytes, but not in resting monocytes [114] . It functions as a monocyte chemoattractant, with no effect on neutrophils or resting lymphocytes. CCL16 binds to CCR1, CCR2, CCR5 and CCR8, but is a less potent agonist than other chemokines that bind to these receptors. As might be expected from its original name, CCL16 is constitutively expressed at high concentrations within the liver by both hepatocytes and biliary epithelial cells [115] . Interestingly, although CCL16 expression is inducible in other cells, treatment of the human hepatoma cell line HepG2 with a variety of cytokines failed to up-regulate CCL16 expression. CCL16 may therefore play a role in the physiological trafficking of inflammatory cells through the liver.
CCL17 [thymus-and activation-regulated chemokine (TARC)]
CCL17 was first identified in phytohaemagglutininstimulated peripheral blood mononuclear cells. CCL17 is constitutively expressed in the thymus and acts as a chemoattractant by binding to CCR4 [116] . There is some debate as to whether CCL17 can also act through CCR8 [117] . CCL17 is a specific chemotactic factor for T cells with a Th2 phenotype, but is also chemotactic for macrophages, NK cells and basophils, and induces platelet activation. CCL17 is produced by keratinocytes, fibroblasts and lipopolysaccharide-stimulated monocytes and certain dendritic cells, and is up-regulated in human pathological conditions associated with infiltration of T cells with a Th2 phenotype, for example allergic respiratory conditions [118] . CCL17 also plays a critical role in the recruitment of skin-homing memory T cells to the sites of skin inflammation and in controlling the inflammatory response through attracting a unique subset of regulatory T cells [119] .
Although development is normal and allergen-induced bronchial hyper-reactivity occurs in CCR4 knockout mice, these genetically modified mice are resistant to the toxic effects of lipopolysaccharide injection, including the associated liver injury [120] . Mice primed with heatkilled Propionibacterium acnes develop severe hepatocellular necrosis following lipopolysaccharide injection. This liver injury is associated with hepatic lymphocyte infiltration and both TNFα-and Fas\Fas ligand-induced hepatocellular necrosis. Injection of P. acnes leads to a granulomatous hepatitis. Preliminary data suggest that there is up-regulation of hepatic CCL3, CXCL9 and CXCL10, and recruitment of Th1 CD4j T cells to the liver. In contrast, following lipopolysaccharide injection, hepatic expression of these chemokines is reduced and CCL17 is up-regulated in macrophage-like cells, with recruitment of Th2-type CCR4-expressing lymphocytes into the liver [121] . Immunoneutralization of CCL17 significantly reduced liver injury and improved survival in this murine model. Furthermore, reduced expression of IL4 by recruited CD4j lymphocytes suggested that neutralization of this chemokine selectively reduced the recruitment of T cells with a Th2 phenotype. There was also a significant decrease in the recruitment of other non-CCR4-expressing effector cells, such as CD8j T cells and NKT cells, indicating that inhibition of CCL17 has immunomodulatory effects beyond the recruitment of cells expressing CCR4.
CCL20 [MIP3α, liver-and activationregulated chemokine (LARC), Exodus 1]
CCL20, as discussed above, was identified in parallel with CCL19 [122] , but had also been cloned and identified by alternative names such as liver-and activationregulated chemokine (LARC) by other groups [123] . CCL20 is expressed constitutively in many different tissues, including liver, and therefore may be important in the homoeostatic trafficking of dendritic cells and lymphocytes through these tissues. The relatively high levels of CCL20 expression in the liver may reflect the great exposure of this organ to potentially infectious micro-organisms, or their products, passing through the gut.
CCL20 is chemotactic for cytokine-stimulated neutrophils, immature dendritic cells and memory\effector T and B lymphocytes by utilizing CCR6 [124] . Expression of CCL20 is up-regulated in certain cell types by lipopolysaccharide and pro-inflammatory cytokines, including TNFα and IL1β. Increased tissue levels of CCL20 have been reported in several inflammatory conditions, such as atopic dermatitis. As such, CCL20 has been implicated as a key chemokine in the arrest of memory T cells on dermal microvascular endothelial cells during inflammation [125] . A recent study has shown expression of CCL20 in macrophages and\or dendritic cells in the livers of patients with chronic viral hepatitis, associated with hepatic infiltration by CCR6-positive lymphocytes [126] . In contrast with other in vitro cell model systems, peripheral blood-derived dendritic cells released CCL20 following phagocytosis of apoptotic hepatoma cells (antiFas-treated Huh-1 cells), linking apoptosis of hepatocytes with a developing inflammatory response [126] . The increased expression of CCR6 on intrahepatic T lymphocytes in normal liver and the high constitutive expression of CCL20 also led these authors to speculate that this chemokine-chemokine-receptor interaction is important in the normal trafficking of T cells through the liver.
CCL21 [6Ckine, secondary lymphoid chemokine (SLC), Exodus 2, thymus-derived chemotactic agent 4]
CCL21 was cloned from a mouse thymic cDNA library, and is expressed in other tissues, including spleen, heart and kidney [127] . CCL21 is chemotactic for mature dendritic cells, naı$ ve and memory T cells, B cells and cultured renal mesangial cells by binding to CCR7 [128] . Murine CCL21 is also able to bind to and signal through CXCR3, in contrast with human CCL21 [129] . Physiologically, CCL21 may function in the homoeostatic recirculation of lymphocytes in vivo. Recent data have also implicated CCL21 in the homoeostatic proliferation of CD4j T cells and progression toward autoimmune disease [130] . Others have highlighted the complexity of the chemokine system and the danger of implicating a role for chemokines in vivo from in vitro data, using CCL21 as an example [131] .
Organ-specific transgenic expression of CCL21 is associated with various inflammatory infiltrates, depending on the site of expression. Increased expression of CCL21 in the pancreas was associated with lymphocyte recruitment and the development of lymphoid node-like structures. In contrast, expression in the brain led to the recruitment of eosinophils and neutrophils, possibly due to the up-regulation of KC, MIP2 and CCL11, and expression in the skin was not associated with any inflammatory infiltration [132] . In vivo studies have shown expression of CCL21 in the small vascular channels associated with portal inflammatory infiltrates in murine granulomatous hepatitis and human cholestatic liver diseases [133, 134] . In the human studies the expression of CCL21 was associated with infiltration with CCR7-expressing lymphocytes. Interestingly, neutralization of CCL21 in the murine model, although reducing portal tract-associated lymphoid tissue, interfered with dendritic cell migration, limiting local and draining lymph node immune responses. This resulted in failure to eliminate the infective agent inducing the granulomata, with persistence of hepatic granulomas and liver damage.
CCL22 [macrophage-derived chemokine (MDC), stimulated T-cell chemoattractant protein 1 (STCP-1)]
CCL22 was identified from a human monocyte-derived macrophage cDNA library. It has very little identity with other CC chemokines. CCL22 is chemotactic for Th2-type lymphocytes, mature dendritic cells and activated NK cells [135] . CCL22 is constitutively expressed by dendritic cells, B lymphocytes and macrophages, and is highly expressed in cytokine-stimulated monocytes\ macrophages and monocyte-derived dendritic cells. Tissue expression has been identified in thymus, lung and spleen. CCL22 acts by binding to the chemokine receptor CCR4 [136] . In keeping with a chemotactic activity for Th2 lymphocytes, this chemokine has been implicated in allergic disease, such as murine models of asthma. CCL22 can also inhibit the entry of HIV into cells. As noted above, CCR4 knockout mice are more susceptible to sepsis. CCL22 plays a central role in the systemic response to sepsis in the murine model of caecal ligation and puncture [137] . This model is associated with significant liver injury. Immunoneutralization of CCL22 increased murine mortality, increased the hepatic expression of TNFα, MIP2, KC and CCL3, and increased hepatic neutrophil infiltration and liver injury. Recombinant CCL22 had the opposite effects, suggesting that this chemokine has an important immunoregulatory role and may be an adjunct to therapy in sepsis.
CCL25 [thymus-expressed chemokine (TECK)]
CCL25 was identified in the thymus of both mouse and human. CCL24 is also expressed in the small intestine, and at lower levels in the liver [138] . At a cellular level, CCL25 is expressed in dendritic cells, but the cellular source within the liver has not been identified. CCL25 is chemotactic for activated macrophages, dendritic cells, T lymphocytes and thymocytes, and inhibits myeloid progenitor proliferation through binding to CCR9 and CCR10 [139, 140] . CCL25 may play a key role in T cell development [141] ; however, T lymphocytes develop normally in CCR9 knockout mice. Perhaps of relevance to hepatocyte apoptosis is the interesting observation that Fas-mediated apoptosis of a human T cell line was partially inhibited by CCL25 [142] .
OTHER CHEMOKINES CX3CL1 (fractalkine)
The chemokine CX3CL1 (fractalkine) has an unusual structure [143, 144] . The gene product for this chemokine contains a transmembrane region and a mucin-like stalk on which a chemokine domain is located. In this chemokine domain the two N-terminal cysteine molecules are separated by three different amino acids. The membrane-bound form of CX3CL1 is induced in activated primary endothelial cells and promotes strong adhesion of T cells and monocytes [145] . Proteolytic cleavage by TNFα-converting enzyme (ADAM17) results in shedding of membrane-bound CX3CL1 from the cell surface [146, 147] . The receptor for CX3CL1 is abundantly expressed in brain and lung tissue, and occurs in other tissues, including the liver. More recent studies have implicated CX3CL1 in the pathogenesis of brain [148] and cardiac [149] disorders, as well as preventing HIV infection of cells [150] .
Our recent studies have implicated CX3CL1 in the hepatic reparative response following paracetamol poisoning because of its unique function in leucocyte trafficking [151] . Constitutive expression of CX3CL1 mRNA was identified in Kupffer cells and hepatocytes, especially the hepatocytes around the central veins. These observations were further explored by studying CX3CL1 knockout and transgenic mice. At 6 h after paracetamol injection, serum transaminases (as a circulating measure of hepatic injury) were significantly increased in the transgenic mice compared with wild-type controls; conversely, serum transaminases were significantly lower in CX3CL1 knockout mice at the same time point. To further investigate the potential for CX3CL1 to augment hepatic injury following paracetamol poisoning via increasing neutrophil influx, hepatic myeloperoxidase was quantified. At 6 and 24 h post-paracetamol, significantly higher hepatic myeloperoxidase levels were found in the transgenic mice compared with the wild-type controls, and significantly lower levels of myeloperoxidase were detected in the liver samples from the knockout mice compared with wild-type controls. In contrast with these data, others have suggested that paracetamol injury may be mediated via extensive Fas-mediated apoptosis of hepatocytes [152] . CX3CL1 is protective against Fasmediated apoptosis in certain brain cells. However, we have not found alterations in mortality or liver injury following Fas injection in CX3CL1 transgenic mice. Other preliminary data have shown up-regulation of CX3CL1 mRNA in the murine concanavalin A hepatitis model; inhibition of chemokine expression is associated with reduced production of pro-inflammatory cytokines and improved survival. Others have shown that both CX3CL1 and its receptor are expressed in human liver tissue following injury; furthermore, the human hepatoma cell line HepG2 expresses both CX3CL1 and its receptor, and cells migrate when exposed to CX3CL1 [153] . These data suggest that overexpression of CX3CL1 in the liver exacerbates liver injury associated with paracetamol poisoning by increasing neutrophil recruitment and oxidative injuries.
XCL1 (lymphotactin)
In contrast with other members of the chemokine superfamily, lymphotactin has just two cysteine residues, only one of which is located at the N-terminus; hence the designation of this chemokine as XCL1 [also known as lymphotactin, single C motif-1 (SCM-1) and activationinduced T-cell-derived and chemokine-related molecule (ATAC)]. In humans there are two closely related proteins, XCL1 and XCL2 (also called SCM-1α), which differ by only two N-terminal amino acids and are the products of two separate genes. The mouse has a single gene and protein product. XCL1 is released from T cells, NK cells, γ\δ T cells and mast cells. XCL1 mRNA was not expressed in human liver tissue when analysed by Northern blot [154] . XCL1 mRNA was most strongly expressed in splenic tissue, and is induced in this organ following murine γ herpes virus-68 infection in IFNγ knockout mice [155] . Incidentally, this model is also associated with reversible hepatic fibrosis and is the subject of further study. Recently the orphan chemokine receptor G-protein-coupled receptor 5 (GPR5) has been identified as the receptor for both XCL proteins, and designated XCR1. Northern blot analysis of XCR1 mRNA has identified expression in human placenta, spleen and thymus, but not human liver.
CONCLUSION
Over the past decade, an increasing number of chemokines have been identified and characterized. This expansion in our knowledge of this family of cytokines has outstripped our understanding of their biological roles. It is now clear that the functions of chemokines include angiogenesis and angiostasis, carcinogenesis and cell cycle control. Recent data have cautioned against the translation of in vitro data into the in vivo or clinical situation. Nevertheless, an understanding of the roles that chemokines play in the pathogenesis of liver disease lags behind that for other conditions such as respiratory disorders or haematological conditions. Chronic liver disease is a major worldwide health problem that is set to become more common with increases in alcohol consumption, the incidence of obesity and the relative frequency of viral hepatitis in most populations. With the increasing development of chemokine or chemokine receptor blocking agents that are effective in treating inflammatory or fibrotic disease, the liver appears to represent fertile ground for further study.
